Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
01-03 May, 2026
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
AMWC Asia-TDAC
Not Confirmed
Contact SupplierAMWC Asia-TDAC
Industry Trade Show
Not Confirmed
01-03 May, 2026
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Digital content
NEWS #PharmaBuzz
06 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/06/3268343/0/en/Neumora-Therapeutics-to-Participate-in-25th-Annual-Needham-Virtual-Healthcare-Conference.html
30 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/30/3264464/0/en/Neumora-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html
16 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/16/3256107/0/en/Neumora-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-Monday-March-30-2026.html
04 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/04/3231884/0/en/Neumora-Therapeutics-to-Participate-in-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html
05 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/05/3212566/0/en/Neumora-Therapeutics-Announces-Positive-Results-from-NMRA-511-Phase-1b-Signal-Seeking-Study-in-Alzheimer-s-Disease-Agitation.html
05 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/05/3212570/0/en/Neumora-Therapeutics-Highlights-2026-Pipeline-Strategy-and-Anticipated-Upcoming-Milestones.html
Drugs in Development
Details:
NMRA-898, a novel small molecule product targeting the M4 muscarinic receptor, shows promise in treating schizophrenia.
Lead Product(s): NMRA-898
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2025
Lead Product(s) : NMRA-898
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neumora Initiates Phase 1 Study of M4 Positive Allosteric Modulator NMRA-898
Details : NMRA-898, a novel small molecule product targeting the M4 muscarinic receptor, shows promise in treating schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2025
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for major depressive disorder.
Lead Product(s): Navacaprant
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2025
Lead Product(s) : Navacaprant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neumora Reports KOASTAL-1 Data for Navacaprant in Major Depression
Details : NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for major depressive disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2025
Details:
NMRA-323511 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Lead Product(s): NMRA-323511
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2024
Details : NMRA-323511 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 09, 2024
Details:
NMRA-511 is an oral potent and selective, best-in-class investigational V1aR antagonist, being investigated for the treatment of agitation associated with dementia due to Alzheimer’s disease.
Lead Product(s): NMRA-511
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 20, 2024
Neumora Starts Phase 1b Study of NMRA-511 for Alzheimer's Agitation
Details : NMRA-511 is an oral potent and selective, best-in-class investigational V1aR antagonist, being investigated for the treatment of agitation associated with dementia due to Alzheimer’s disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 20, 2024
Details:
NMRA-335140 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major-associated with Bipolar Disorder.
Lead Product(s): NMRA-335140
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2024
Lead Product(s) : NMRA-335140
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NMRA-335140 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major-associated with Bipolar Disorder.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 28, 2024
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for bipolar depression.
Lead Product(s): Navacaprant
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2024
Lead Product(s) : Navacaprant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neumora Announces Initiation of Ph 2 Study of Navacaprant in Bipolar Depression
Details : NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for bipolar depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2024
Details:
Neumora's investigation product NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor. It is being evaluated in the clinical trials for the treatment of Schizophrenia.
Lead Product(s): NMRA-266
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2024
Lead Product(s) : NMRA-266
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Details : Neumora's investigation product NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor. It is being evaluated in the clinical trials for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2024
Details:
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia.
Lead Product(s): NMRA-266
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 27, 2023
Lead Product(s) : NMRA-266
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
Details : NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 27, 2023
Details:
NMRA-335140 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): NMRA-335140
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023
Lead Product(s) : NMRA-335140
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NMRA-335140 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 28, 2023
Details:
NMRA-335140 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): NMRA-335140
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023
Lead Product(s) : NMRA-335140
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Details : NMRA-335140 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
